1. To investigate the relative roles of angiotensin I1 (AH) and des-Asp1-angiotensin I1 (angiotensin 111) in the control of blood pressure and aldosterone release, the effects of seven angiotensin agonists on mean arterial blood pressure and serum aldosterone concentrations were compared in normal and sodium-depleted, conscious rats.
Introduction
In sodium depletion, the physiological responses to exogenous A11 differ from those observed in the normal sodium state. Most notably, the ability of 326
W. B. Campbell, J. M . Schmitz and H. D. Itskovitz
A11 to elevate the blood pressure is suppressed and its ability to stimulate aldosterone release is enhanced (Hollenberg, Chenitz, Adams & Williams, 1974; Oelkers, Brown, Fraser, Lever, Mor- ton & Robertson, 1974; Deheneffe, Cuesta, Briggs, Brown, Fraser, Lever, Morton, Robertson & Tree, 1976; Kinson & Singer, 1968; Campbell, Schmitz & Itskovitz, 1977a) . By comparison, angiotensin I11 (des-Asp1-AII) has less vasopressor activity than A11 but equal or greater aldosterone-releasing ability in normal animals and adrenal cell suspensions (Blair-West, Coghlan, Denton, Funder, Scoggins & Wright, 1971; Campbell, Brooks & Pettinger, 1974; Campbell & Pettinger, 1976; Freeman, Davis, Lohmeier & Spielman, 1976; Chiu & Peach, 1974; Peach, Sarstedt & Vaughan, 1976) . After sodium depletion, adrenal cells are much more sensitive to A111 than to A11 in releasing aldosterone (Peach et al., 1976) , but we have shown that exogenous A11 is more potent than A111 in raising aldosterone concentrations in the sodium-depleted rat (Campbell et al., 1977a) ; The nonapeptide desl-Asp-A1 can also produce vasoconstriction and enhance aldosterone release when infused into conscious rats (Campbell, Schmitz & Itskovitz, 1977b; Larner, Vaughan, Tsai & Peach, 1977) . However, the vasopressor and steroidogenic effects of desl-Asp-A1 appeared to depend primarily on its conversion in viuo into A111 since its vasoconstrictor and aldosteronereleasing activities were greatly reduced by inhibition of converting enzyme.
We have now studied the roles of A11 and AIII in the control of blood pressure and aldosterone release in normal and sodium-depleted states. The physiological effects of A11 were compared with those of the other naturally occurring peptides AI, des-Asp'-A1 and AIII as well as with three synthetic analogues of angiotensin in normal and sodium-depleted animals. Since A11 can be readily converted into A111 by plasma and adrenal aminopeptidases, the synthetic analogues of AII, pAsp1-A11 and poly-0-acetylserine-A11 were selected for these studies because of their resistance to this degradation. These analogues allowed us to examine selectively the physiological effects of the octapeptide molecule. Finally, the physiological role of endogenous angiotensins was studied by using antagonsists of A11 and AIII.
Methods
We studied groups of six male SpraguCDawley rats (250-300 g) that were placed in individual metabolism cages and kept on a normal sodium diet for 3 days followed by 5 days sodium depletion. On the normal diet, the rats ingested 3.7 0.1 mmol of Na/day and 6.6 k 0.2 mmol of K/day (Purina Rat Chow: 150 mmol of Na/kg, 270 mmol of K/kg). On the sodium-deficient diet. they ingested 0.14 f 0.1 mmol of Na/day and 3.2 0.1 mmol of K/day (Nutritional Biochemical Co.: 10 mmol of Na/kg, 220 mmol of K/kg). Frusemide (30 pmollkg) was administered intraperitoneally during the first day of dietary alteration in the sodium-depleted group. During the first 2 days after dietary alteration, the rats were in negative sodium balance. Thereafter, sodium output matched sodium input. Sodium depletion did not alter potassium balance.
In the studies involving blood pressure measurements, chronic catheters (Weeks, 1973) were placed in the jugular vein of each rat for intravenous injections, and in the descending aorta for measurement of blood pressure 2-5 days before the experiment (Campbell & Pettinger, 1976; Campbell et al., 1977b) . Angiotensin I (Beckman), des-Asp'-A1 (Campbell et al., 1977b) , cc-Aspl-AII (Beckman), P-Asp1-A11 (Beckman), angiotensin 11-amide (Ciba-Geigy), poly-0-acetylserine-A11 (Cleveland Clinic), angiotensin I11 (Beckman), noradrenaline (Sigma Chemical) or 0.28 mol/l glucose solution was injected intravenously in a constant volume (10 pl) into groups of normal and sodium-depleted rats. The potency of each peptide was determined by the ED,, (the dose required to cause a 20 mmHg increase in blood pressure), and compared with that of a-Asp-AII. In another group of rats, an injection of the angiotensin antagonist Sarl-Iles-AII (Beckman) (1033 pmol/kg) or Ile7-AIII (Beckman) (1116 pmol/kg) was given subcutaneously followed after 5 min by a 20 min infusion of the same antagonist at a rate of 517 (Sarl-Iles-AII) or 558 (Ile7-AIII) pmol min-l kg-I. The control animals were infused with 0.28 moVl glucose at a rate of 50 pl/min for 20 min. The effects of the peptide on mean arterial blood pressure were monitored with a Narco RP-1500 pressure transducer and a Grass model 7 Polygraph.
In the steroid studies, normal and sodiumdepleted groups of rats had chronic catheters implanted into their jugular veins 18 to 24 h before experimental procedures (Campbell & Pettinger, 1976; Campbell et al., 1977b; Weeks, 1973) . All subsequent studies were performed without anaesthesia between 08.00 and 12.00 hours to minimize variations in steroid concentrations due to diurnal rhythm, anaesthetic and surgical stress (Campbell et al., 1974; Campbell & Pettinger, 1976) . Control animals were infused intravenously with glucose (0.28 mol/l) at a rate of 50 p h i n for 20 min. Experimental animals were infused at a similar rate with one of the angiotensin polypeptides in glucose solution (0.28 mol/l). The potency of the peptides was assessed in terms of their abilities to increase in serum aldosterone by 60 pmol/dl and compared with that obtained with a-Asp-AII. Immediately after each infusion, the animals were decapitated and aortic blood was collected into plastic tubes in ice. The blood was allowed to clot at 4OC, centrifuged in the cold, and the serum removed. The serum was stored at -2OOC until thawed on ice for determination of aldosterone concentrations by radioimmunoassay using a modified method of Gomez-Sanchez, Kern & Kaplan (1973) . Since the metabolic clearance rate of aldosterone is not altered by sodium depletion (Bojesen, 1966) , changes in serum aldosterone reflected the changes in aldosterone secretory rate.
Statistical differences in responses between each group of rats were assessed by unpaired t-test whereas an analysis of covariance was used for statistical assessment of dose-response curves (Snedecor & Cochran, 1967) . Values are given as mean f SEM.
Results
The mean arterial blood pressure was 108 f 6 mmHg in normal and 103 f 12 mmHg in sodiumdepleted rats in the control periods. A11 and noradrenaline caused dose-related increases in mean arterial blood pressure in both groups of rats ( Fig. 1) . In normal animals, A11 was 50 times more potent than noradrenaline in its ability to increase mean arterial pressure by 20 mmHg. Sodium depletion diminished the pressor activity of A11 by 65% (P < 0.01) whereas the pressor activity of noradrenaline was reduced by only 18% (P > AI, AII, AIII, and des-Asp-A1 caused doserelated increases in mean arterial pressure in both groups of rats (Fig. 2) . With normal salt intake, A1 and A11 were equipotent in their ability to increase blood pressure. Significant increases in mean arterial pressure were measured at doses of 3 pmol/kg (P < 0.001). In contrast, A111 and desAsp-A1 were 25% as potent as A11 (P < 0.01).
After sodium depletion, dose-response curves for each of the angiotension peptides were shifted to
0.1).
the right. Doses of 30 pmol/kg for A1 and A11 and 300 pmol/kg for A111 and des-Asp-A1 were then required to increase blood pressure significantly. In comparison with normal animals, the pressor activity of A1 was reduced by 64% (P < OaOl), A11 by 66% (P < 0.01). A111 by 85% (P < 0-01), and des-Asp-A1 by 79% (P < 0.01) after sodium depletion.
Comparisons of the pressor activities of three synthetic analogues of A11 modified at the Nterminal position are shown in Fig. 3 , in normal and sodium-depleted rats. b-Asp-A11 and AIIamide were equipotent with A11 in pressor ability in normal rats, requiring a threshold dose of 3 pmol/kg. A111 was 28% (P < 0.01) and poly-0-acetylserine-A11 was 41% (P < 0.01) as potent as AII, requiring threshold doses of 30 pmol/kg to induce significant blood pressure elevations. Whereas sodium depletion significantly reduced the pressor activities of each of these peptides (P < 0.01), their relative potencies were of the same order as in normal animals except for AIII, which was only 11% (P < 0.01) as potent as AII.
In normal rats, AI, A11 and A111 increased the serum aldosterone concentration at doses of 3 pmol min-I kg-I (P < 0.001, 
FIG. 2. Effect of angiotensin
angiotensin 111 (AIII,----), and des-Asp1-angiotensin I (des-Asp AI, .-.-) on the change in mean arterial pressure (AMAP) in normal (a) and sodium-depleted (b) conscious rats. Each point represents the mean k SEM for eight rats. **P < 0.01; ***P < 0.001.
-
angiotensin 11-amide (. . . . .), angiotensin 111 (. ---), and poly-0-acetylserine-angiotensin I1 (----) on change in mean arterial pressure (AMAP) in normal (a) and sodium-depleted (b) rats. Each point represents the mean k SEM for eight rats. **P < 0.01; ***P < 0.001.
, and des-Asp-AI 5% enhanced as indicated by significant increases in (P < 0.001) as potent as AII. After sodium the slope of the dose-response curves (P < 0.01).
depletion, the control serum aldosterone concenAs with normal sodium intake, A11 and A111 tration increased from 7.2 f. whereas a dose of 30 pmol min-' kg-' was required for A1 (P < 0.01) and 300 pmol min-' kg-' for des-Asp-A1 (P < 0.00 1). Des-Asp-A1 significantly suppressed the serum aldosterone concentrations at the 3 (P < 0.01) and 30 (P < 0-02) pmol min-' kg-' doses in those studies. Sodium depletion increased the steroidogenic potency of A11 to a greater extent than the other angiotensin peptides. In sodium depletion, A111 was only 27%, A1 7%, and des-Asp-A1 1% as potent as A11 (P < 0.001) in their respective abilities to raise the serum aldosterone concentrations.
As with the naturally occurring angiotensin peptides, the synthetic analogues induced doserelated increases in serum aldosterone concentrations in normal and sodium-depleted rats (Fig.  5) . In normal rats, @-Asp-AII, AIII, and AII-amide were equipotent with A11 in their abilities to release aldosterone. All four peptides significantly increased serum aldosterone concentrations at the 3 pmol min-' kg-' dose (P < 0401). After sodium depletion, there were marked differences in the response. The potency of A11 increased relative to the other peptides. @-Asp-A11 and A111 were next in potency (27% as potent as AII) whereas AII-amide exhibited only 3% the potency of A11 for increasing serum aldosterone concentrations in sodium- for eight rats. **P < 0.01; ***P < 0.001.
depleted rats. Angiotensin I11 significantly increased the aldosterone concentrations at a dose of 3 pmol min-' kg-' (P < 0.05) whereas @-Asp-A11 required a dose of 30 pmol min-l kg-' (P < 0.0 1); however, the dose-response curves for the two peptides did not differ significantly (P > 0.1).
Comparison of the steroidogenic effects of equipressor doses of A11 (2.9 pmol min-' kg-'), A111 (32 pmol min-' kg-I), and poly-0-acetylserine-A11 (4lpmol min-' kg-') (Table l), shows that in both normal and sodium-depleted rats, the poly-0-acetylserine-A11 was significantly less active in stimulating aldosterone release than either A11 or Table 2 shows the effects of the A11 antagonist (Campbell et al., 1974; Campbell & Pettinger, 1976; Freeman et al., 1976; Chiu & Peach, 1974) , Sarl-Iles-AII, and the A111 antagonist (Sarstedt, Vaughan & Peach, 1975; Bravo, Khosla & Bumpus, 1975) , Ile7-AIII, on blood pressure and aldosterone release in normal and sodium-depleted rats. In normal animals, neither antagonist altered the blood pressure significantly at these doses. However, both peptides increased the serum aldosterone concentrations significantly in normal rats (P < 0.05). Ile7-AIII was more active than SarlIle8-A11 in this respect. After sodium depletion, A111 (P < 0.05). Sar'-Ile8-AII decreased the mean arterial blood pressure significantly from 109 f 4 mmHg to 88 + 8 mmHg (P < 0.01) whereas Ile7-AIII had no significant effect. However, Ile7-AIII suppressed the serum aldosterone concentration by 61% (P < 0.01) whereas this dose of Sar1-Ile8-AII did not significantly alter the serum aldosterone concentrations.
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Discussion
We administered seven angiotensin agonists to normal and sodium-depleted rats, and measured changes in blood pressure and serum aldosterone. Qualitatively, the pressor responses of angiotensin were diminished by sodium depletion, whereas the aldosterone release was enhanced. Unlike the angiotensins, the pressor responses to noradrenaline were not significantly altered in normal rats as compared with sodium-depleted rats. This suggests that there is a specific relationship between sodium metabolism and angiotensin vascular responsiveness, apart from general alterations in vascular smooth muscle reactivity or hypovolaemia. This reduced responsiveness to angiotensin after sodium depletion may result from either a reduced affinity of vascular angiotensin receptors (Williams, Hollenberg & Braley, 1976) , prior occupancy of the available receptors (Brunner, Chang, Wallach, Sealey & Laragh, 1972; Thurston & Laragh, 1975) or reduction in the number of vascular angiotensin receptors (Chevillotte, Devynck, Fyhrquist, Meyer, Rouzaire-Dubois & Worcel, 1975) . The relative roles of these three mechanisms in determining the activity of angiotensin remains to be determined. In the adrenal gland, the enhanced response of aldosterone release to angiotensin after sodium depletion may be related to an increased conversion of corticosterone into aldosterone (Campbell et al., 1977a; Blair-West, Brodie, Coghlan, Denton, Flood, Goding, Scoggins, Tait, Tait, Wintour & Wright, 1970; Muller, 1971) , an increase in the number of angiotensin adrenal cortical receptors (Douglas & Catt, 1976) or an enhanced production of A111 (Peach et af., 1976). We have now studied this lastnamed hypothesis.
Our results in uiuo indicate that the pressor response to A11 is reduced less by sodium depletion than the response to AIII, while its steroidogenic activity is enhanced more than that of AIII. Peach et af. (1976) , using adrenal cell suspensions from normal and sodium depleted rats, observed a different steroidogenic response, finding that A11 Angiotensins in sodium depletion 33 1 was only one-tenth as potent as A111 in adrenal cell suspensions from sodium-depleted animals, whereas in vivo we found A11 to be four times more potent than A111 in stimulating steroidogenesis in similarly sodium-depleted animals. Thus, our studies in vivo indicate that A11 functions as the predominant peptide controlling steroidogenesis in sodium depletion, whereas Peach et al. (1976) indicate that A111 exerts this function in vitro. If, on the other hand, adrenal cells in vivo are actually sensitized by sodium depletion to such an extent to the steroidogenic action of AIII, our results would indicate that 97% of infused A111 must be inactivated before reaching the adrenal cortical receptors in sodium depletion. This explanation is consistent with a greater reduction in the pressor activity of AIII, as compared with A11 (85% for A111 vs 66% for AII), as well as the enhanced inactivation of angiotensin in sodium depletion (Leary & Ledingham, 1970; Johnston, Mendelsohn & Doyle, 1972) . These findings would then suggest that the aspartyl group in position 1 of the A11 molecule functions to prolong the activity of the peptide by protecting it from the action of circulating aminopeptidases, allowing greater quantities of the active peptide to reach the receptors.
The studies with N-terminally modified analogues of A11 further substantiate this contention and provide several perspectives on the relative importance of A11 and A111 in states of normal and low sodium. Whereas AII, 8-Asp-AI1, and AIIamide were equipotent as steroidogenic agents in normal rats, A11 was four times more potent than PAsp-A11 and 30 times more potent than AIIamide after sodium depletion. Although these steroidogenic differences may reflect changes in receptor affinity for the various angiotensin agonists after sodium depletion (Williams et al., 1976; Douglas & Catt, 1976) , they may also be due to differences in N-terminal metabolism by plasma or tissue angiotensinases. Since A11 can be readily converted into A111 by aminopeptidase A in the plasma and adrenal cortex (Campbell & Pettinger, 1976 ; Bumpus, Smeby, Page 8c Khairallah, 1964; Khairallah, Bumpus, Page & Smeby, 1963; Regoli, Riniker & Brunner, 1963; Nagatsu, Gillespie, Folk & Glenner, 1965) , its pressor and steroidogenic effects must be a result of the combined actions of the octapeptide and heptapeptide molecules. On the other hand, 8-Asp-A11 is resistant to aminopeptidases, but is metabolized in the adrenal by an endopeptidase (Bumpus et al., 1964; Khairallah et al., 1963; Regoli et al., 1963) , which catalyses the formation of peptide fragments which have little steroidogenic activity. Thus, the actions of 8-Asp-A11 must be attributed primarily to a direct effect of the octapeptide molecule. With this line of reasoning it would appear that A11 can stimulate aldosterone release independently of any conversion into AIII, since a-Asp-A11 and 8-Asp-A11 produced identical steroidogenic effects. After sodium depletion, both peptides retained significant steroidogenic activity; however, a-Asp-A11 was four times more potent than 8-Asp-AII. Thus, unlike the normal sodium state, the steroidogenic response to A11 in sodium-depleted rats seems to be a combination of the effects of the octapeptide per se as well as an additional component provided by the formation of the heptapeptide, AIII. Similarly, coupling poly-0-acetylserine to the N-terminus of A11 can also protect the peptide from plasma and adrenal aminopeptidase degradation (Bumpus et al., 1964; Khairallah et al., 1963) . In our studies, poly-0-acetylserine-A11 was also less potent than A11 or A111 in stimulating aldosterone release in both normal and sodium-depleted animals. Unlike pAsp-AII, however, the interpretation of the effects of poly-0-acetylserine-A11 is complicated by steric factors which may be contributed by poly-0-acetylserine. However, our results clearly show that in both normal and low sodium states, A11 can stimulate aldosterone release independently of any N-terminal degradation by aminopeptidases. Finally, AII-amide undergoes rapid N-terminal degradation to the hexapeptide, and possibly to the heptapeptide, by plasma aminopeptidases, which differ from those acting on A11 (Regoli et al., 1963; Nagatsu et al., 1965; McDonald, Zeitman, Callaghan & Ellis, 1974; Khairallah & Page, 1967) . Although the reason for the relatively weak steroidogenic effect of AII-amide is unknown, it may be that increased proportions of heptapeptide and hexapeptide formed from AII-amide are rapidly inactivated on reaching the adrenal, to form smaller fragments similar to circulating AIII.
Others have reported that Sari-A11 was more potent than A11 or A111 in stimulating aldosterone release in normal animals (Bravo et al., 1976; Fredlund, Saltman & Catt, 1975; Saltman, Fredlund & Catt, 1976; Bravo, Khosla & Bumpus, 1976a, b) . Since Sari-A11 resists metabolism by aminopeptidase A (Hall, Khosla, Khairallah & Bumpus, 1974) , it was concluded that A11 had steroidogenic activity independent of its conversion into AIII. Our observations with P-Asp-AII support this conclusion with one additional advantage.
Although Sari-A11 is not metabolized by aminopeptidase A, it can be converted into A111 by leucine aminopeptidase (Hall et al., 1974) , which is abundant in the plasma and adrenal cortex (Campbell & Pettinger, 1976) . Therefore, the possibility that the formation of A111 contributes to its steroidogenic activity cannot be eliminated. In contrast, P-Asp-A11 is not metabolized by either of these aminopeptidases (Bumpus et al., 1964; Khairallah et al., 1963; Regoli et al., 1963) so its steroidogenic activity must represent a direct action of the intact octapeptide molecule.
In normal rats, neither Sar1-Ile8-AII nor Ile7-A111 affected blood pressure whereas both significantly elevated aldosterone concentrations, demonstrating their partial agonistic properties. After sodium depletion, Sari-Ilea-A11 decreased blood pressure without affecting the elevated aldosterone concentrations; however, Ile7-AIII had an opposite effect, to decrease aldosterone without altering blood pressure. This occurred despite our observation that in the same doses, Sari-Ilea-A11 was more potent than Ile7-AIII, in blocking both the pressor and steroidogenic effects of exogenous A11 and A111 in normal rats (Campbell & Schmitz, 1979) . Thus in sodium depletion, the A111 antagonist was more potent in blocking steroidogenesis and the A11 antagonist was more potent in blocking vasoconstriction (Sarstedt et al., 1975;  Table 2 ). These findings give further evidence that A11 is a major regulator of aldosterone secretion in sodium depletion, and that A111 participates in this steroidogenic activity.
In summary, our studies indicate that A11 functions as a major regulator of aldosterone secretion in normal and sodium-depleted rats, and that the conversion of A11 into A111 is not essential for this action. After sodium depletion, the steroidogenic responses to A11 are enhanced while its pressor effects are reduced; however, it is unlikely that these effects are due only to an increased conversion of A11 into AIII, since the steroidogenic and pressor responses to /?-Asp-A11 are similarly altered. As A11 was four times more potent than P-Asp-A11 in stimulating aldosterone release in sodium-depleted rats, and as Ile7-AIII was more effective than Sari-Ilea-A11 in reducing aldosterone release in sodium depletion, some of the steroidogenic effect of A11 may be is due to its conversion into AIII.
